249 related articles for article (PubMed ID: 18549935)
21. Multiple myeloma with myelomatous pleural effusion: a case report and review of the literature.
Kim YJ; Kim SJ; Min K; Kim HY; Kim HJ; Lee YK; Zang DY
Acta Haematol; 2008; 120(2):108-11. PubMed ID: 18957845
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
Thomas R; Cheah HM; Creaney J; Turlach BA; Lee YC
Chest; 2016 Jun; 149(6):1494-500. PubMed ID: 26836920
[TBL] [Abstract][Full Text] [Related]
23. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
24. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
Yan TD; Boyer M; Tin MM; Sim J; Kennedy C; McLean J; Bannon PG; McCaughan BC
Ann Thorac Surg; 2009 May; 87(5):1552-6. PubMed ID: 19379903
[TBL] [Abstract][Full Text] [Related]
25. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.
Tanrikulu AC; Abakay A; Kaplan MA; Küçüköner M; Palanci Y; Evliyaoglu O; Sezgi C; Sen H; Carkanat Aİ; Kirbas G
Respiration; 2010; 80(6):480-7. PubMed ID: 20881372
[TBL] [Abstract][Full Text] [Related]
26. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
Hsu LH; Hsu PC; Liao TL; Feng AC; Chu NM; Kao SH
BMC Cancer; 2016 Jul; 16():463. PubMed ID: 27411914
[TBL] [Abstract][Full Text] [Related]
27. The distinction between transudates and exudates.
Gonlugur U; Gonlugur TE
J Biomed Sci; 2005 Dec; 12(6):985-90. PubMed ID: 16228298
[TBL] [Abstract][Full Text] [Related]
28. [Pleural mesothelioma: experience with 62 cases in 9 years].
Villena Garrido V; López Encuentra A; Echave-Sustaeta J; Alvarez Martínez C; Rey Terrón L; Sotelo MT; Ballestín C
Arch Bronconeumol; 2004 May; 40(5):203-8. PubMed ID: 15117619
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and management of malignant pleural effusions.
Heffner JE
Respirology; 2008 Jan; 13(1):5-20. PubMed ID: 18197908
[TBL] [Abstract][Full Text] [Related]
30. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
32. Sestrin-2 is significantly increased in malignant pleural effusions due to lung cancer and is potentially secreted by pleural mesothelial cells.
Tsilioni I; Filippidis AS; Kerenidi T; Budanov AV; Zarogiannis SG; Gourgoulianis KI
Clin Biochem; 2016 Jun; 49(9):726-728. PubMed ID: 26874199
[TBL] [Abstract][Full Text] [Related]
33. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).
Verma A; Abisheganaden J; Light RW
Lung; 2016 Feb; 194(1):147-53. PubMed ID: 26678281
[TBL] [Abstract][Full Text] [Related]
34. Soluble triggering receptor expressed on myeloid cells-1 for diagnosing empyema.
Bishara J; Goldberg E; Ashkenazi S; Yuhas Y; Samra Z; Saute M; Shaked H
Ann Thorac Surg; 2009 Jan; 87(1):251-4. PubMed ID: 19101307
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.
Shi XY; Yi FS; Wang Z; Qiao X; Zhai K
Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116
[TBL] [Abstract][Full Text] [Related]
36. Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK Centers.
Bibby AC; Clive AO; Slade GC; Morley AJ; Fallon J; Psallidas I; Pepperell JCT; Slade MG; Stanton AE; Rahman NM; Maskell NA
Chest; 2015 Jul; 148(1):235-241. PubMed ID: 25429399
[TBL] [Abstract][Full Text] [Related]
37. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.
DiBonito L; Falconieri G; Colautti I; Bonifacio D; Dudine S
Acta Cytol; 1992; 36(3):329-32. PubMed ID: 1580116
[TBL] [Abstract][Full Text] [Related]
38. Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor.
Pokieser W; Cassik P; Fischer G; Vesely M; Ulrich W; Peters-Engl C
Breast Cancer Res Treat; 2004 Jan; 83(2):139-42. PubMed ID: 14997044
[TBL] [Abstract][Full Text] [Related]
39. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
